This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.
progress to cancer. Despite such screening, in 2008, approximately 11,000 women in the United States received a diagnosis of cervical cancer and 3900 died from the disease. 5 The direct medical costs associated with the prevention and treatment of HPV-related anogenital warts and cervical disease in the United States are estimated to be $4.0 billion annually,6 and productivity losses due to deaths from cervical cancer are estimated to be $1.3 billion annually. 7 
Pathophysiological Features and Effect of Therapy
HPVs are double-stranded DNA viruses that infect cutaneous or mucosal epithelial surfaces. The genome of the virus encodes two nucleocapsid proteins (L1 and L2) and at least six early proteins (E1, E2, and E4 through E7) that allow for replication of viral DNA and the assembly of viral particles. The HPV life cycle occurs only in keratinocytes undergoing differentiation ( Figure   1 ). In most cases, infection occurs without malignant transformation. In such cases, the viral DNA is maintained separately from the host DNA as an episome. In the subgroup of HPV infections leading to malignant transformation, the viral DNA is often integrated into the host genome during progression of the cancer. Carcinogenesis is associated with the expression of proteins E6 and E7, which inactivate tumor suppressors p53 and retinoblastoma protein (pRb), respectively.19 In terms of clinical efficacy, neither the incidence of invasive cervical cancer nor the rate of death due to cervical cancer has been assessed as a trial end point for either vaccine. Although the prevention of such outcomes is of course the ultimate purpose of HPV vaccination, they are infrequent enough that a very large, long-term trial would be necessary to establish such a benefit. Such studies are ongoing.28 Furthermore, treatment for precancerous lesions would be expected to reduce event rates still further, since it would not be ethical to allow the development of advanced disease without intervention in a trial participant with a known precursor. Therefore, the major trials have used prevention of CIN 2, CIN 3, and adenocarcinoma in situ as the efficacy end points. 
Ideally, young women should be vaccinated before they have sexual intercourse for the first time, since they often acquire HPV infection within months after their first sexual intercourse, and the peak incidence of HPV infection occurs within a few years after that. In the United States, 6.2% of adolescents have sexual intercourse for the first time before 13 years of age, and the median age at the time of first sexual intercourse is 16 to 17 years.34
The vaccine should not be given to women with a history of an immediate hypersensitivity to yeast or to any component of the vaccine, and immunization should be deferred in young women with moderate-to-severe acute illness. Vaccination is covered by some, but not all, health insurance plans, and some, but not all, states have passed legislation providing state funding for vaccination.4344
Adverse Effects
In clinical trials of the quadrivalent vaccine, mild adverse events that were more common in vaccine recipients than in placebo recipients included pain, erythema, and swelling at the injection site, as well as headache, fatigue, and myalgia. Rates of serious adverse events were not higher among recipients of vaccine than among recipients of placebo for either vaccine. States; as of that date, the VAERS database included 11,916 reports of adverse events after HPV vaccination.46 Of these events, 94% were considered to be nonserious; they included dizziness, syncope, nausea, pain at the injection site, headache, fever, and rash. The 6% of events that were considered to be serious included Guillain-Barré syndrome, venous thromboembolism, and death. The CDC and the FDA have concluded that these events do not appear to be causally linked to the vaccine.46
Clinically significant adverse events should be reported by clinicians or patients to VAERS so that they can be investigated. VAERS reporting forms and information are available at www.vaers.hhs.gov or by calling 800-822-7967.
Areas of Uncertainty
Several areas of uncertainty remain with regard to HPV vaccination. First, the duration of immunogenicity and clinical efficacy is unknown. Long-term cohort studies of vaccinated women are being conducted to address this question and to establish whether boosters are needed.28 Second, the efficacy of vaccination in men is not well 
Recommendations
The young woman described in the vignette is 18 years of age and therefore an appropriate candidate for HPV immunization. I recommend that the HPV vaccine be universally administered to young women of this age, regardless of their history of sexual activity, unless there are contraindications to vaccination. In order to avoid vaccination during pregnancy, I would assess the risk of pregnancy and perform a pregnancy test, if indicated, in this sexually active young woman. I would also explain that although she may have already been exposed to HPV through sexual contact, she is unlikely to be infected with both of the cancer-associated HPV types targeted by the quadrivalent HPV vaccine, so vaccination would be expected to protect her at least partially. Finally, I would use this opportunity to reinforce the importance of both practicing safe sexual behaviors to prevent sexually transmitted infections and returning for future Pap screening, since current vaccines do not target all high-risk HPV types and the duration of efficacy is unknown.61
